Roopa Industries Limited is an established Indian pharmaceutical entity specializing in the manufacturing of **Bulk Drugs**, **Drug Intermediates**, and **Pharmaceutical Formulations**. Founded in **1985**, the company has evolved into a specialized manufacturer with a strong focus on indigenous technology and niche chemical compounds. Operating from its centralized facility in **Telangana**, the company serves both acute and chronic therapeutic segments within the domestic and international pharmaceutical markets. --- ### **Core Product Portfolio and Market Specialization** The company’s business model is anchored by a single-segment focus on **Bulk Drugs and Intermediates**, with a strategic emphasis on high-demand chemical compounds. * **Flagship Product: Triphenyl Phosphine (TPP):** This serves as the primary revenue driver. The company is focusing on brand building and customized marketing for TPP to capture growing opportunities in global and domestic supply chains. * **Key Intermediates:** The company maintains a strong market position in the production of **Iminodibenzyl (IDB)** and **Iminodibenzyl Carbonyl Chloride (IDBCC)**. * **Therapeutic Reach:** Products are designed to cater to a wide array of medicinal formulations across multiple therapeutic categories, addressing the rising healthcare awareness and expanding insurance coverage in the Indian market. --- ### **Manufacturing Infrastructure and R&D Capabilities** Roopa Industries operates with a philosophy of technological self-reliance, utilizing **100% indigenous technology** across its production lines. * **Strategic Location:** The manufacturing base is situated at **A3, A4, Phase-IV, IDA, Patancheru, Telangana**. * **In-house R&D Division:** The company operates a dedicated R&D wing focused on: * **Process Optimization:** Improving indigenous technology to enhance yield and reduce costs. * **Quality Enhancement:** Ensuring products meet world-class standards to remain competitive against global players. * **Productivity:** Continuous innovation to streamline manufacturing cycles. * **Technology Independence:** The company has **not imported any technology** in the last **three years**, relying entirely on internal development to drive its product portfolio. --- ### **Financial Performance and Capital Structure** The company has demonstrated significant top-line growth, nearly doubling its turnover in the most recent fiscal period. #### **Comparative Operational Highlights** | Metric | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Sales Turnover** | **₹120.69 Crore** | **₹70.43 Crore** | **₹75.89 Crore** | | **Working Capital** | - | **₹6.08 Crore** | **₹2.51 Crore** | | **Cash & Equivalents** | - | **₹2.98 Crore** | **₹1.95 Crore** | | **Inventories** | - | **₹25.16 Crore** | **₹18.38 Crore** | #### **Capital and Liquidity Position** * **Equity Base:** The **Authorised Share Capital** is **₹9.00 Crore**, with a **Paid-up Equity Capital** of **₹7.87 Crore** (comprising 78,65,520 shares at **₹10** face value). * **Other Equity:** Increased to **₹7.07 Crore** in 2024 from **₹6.08 Crore** in 2023. * **Credit Flexibility:** The company has improved its liquidity buffer, reporting **unutilized credit limits** of **₹69.41 Lakhs** in 2024, a substantial increase from the **₹1.29 Lakhs** available in the prior year. * **Asset Quality:** **Trade Receivables** stood at **₹8.35 Crore** as of March 31, 2024, and are classified by management as "good and realizable." --- ### **Leadership and Corporate Governance** The company prioritizes leadership stability and strict adherence to the **Companies Act, 2013**. * **Executive Continuity:** **Mr. Tumbalam Gooty Raghavendra** has been re-appointed as **Chairman and Managing Director** for a **3-year term** effective **October 1, 2024**. * **Governance Compliance:** As the Chairman has crossed the age of **70**, the company operates under a **special resolution** per **Section 196 3(a)** to retain his expertise. * **Remuneration Standards:** Executive pay is aligned with **Schedule V** of the Companies Act. The ratio of the CMD’s remuneration to the median employee remuneration is **15.16**. * **Insider Trading:** The company strictly enforces a **Code of Conduct** in compliance with **SEBI (Prohibition of Insider Trading) Regulations, 2015**. --- ### **Operational Risk Profile and Mitigation** Roopa Industries navigates a complex landscape of industrial, financial, and regulatory risks. #### **Industrial and Asset Risks** * **Fire Incident (November 2025):** A significant fire at the **Patancheru Plant** impacted a storage room containing raw materials and finished goods. * **Estimated Loss:** **₹4.09 Crore** across inventory and machinery. * **Status:** Insurance claims have been filed; restoration of full operations is underway. * **Inventory Pressure:** To meet "just-in-time" buyer requirements, the company maintains high inventory levels (**₹25.16 Crore**), which can strain liquid resources. #### **Financial and Market Risks** * **Currency Exposure:** The import of **Triphenyl Phosphineoxide (TPPO)** and **Triphosgene** exposes the company to foreign exchange volatility. * **Raw Material Volatility:** Profitability is highly sensitive to the fluctuating market prices of chemical inputs. * **Related Party Concentration:** The company has significant transaction volumes with related entities like **Sree Rayalaseema Hi-strength Hypo Limited**. In certain periods, these transactions have reached **100%** of the previous year's turnover. #### **Internal Controls and Audit Observations** The company is currently addressing several "material weaknesses" identified in recent audits: * **Audit Trail:** The company was **non-compliant** with the **Edit Log (Audit Trail)** requirements for FY 2023-24 but has committed to implementation for **FY 2024-25**. * **Verification Issues:** Auditors noted a lack of physical inventory verification by management in 2024 (relying instead on external experts) and a lack of external balance confirmations for payables and receivables. * **Auditor Transition:** The previous statutory auditors resigned, citing **low audit fees** as the primary reason. --- ### **Human Capital and Regulatory Compliance** * **Workforce:** The company employs a permanent staff of **59 employees**. * **Labor Codes:** Wage structures have been updated to align with the **Code on Wages 2019** and the **2020 Labour Codes**. * **Gratuity and Actuarial Risk:** The company faces potential **Asset-Liability Mismatch** in its gratuity obligations, as the duration of liabilities exceeds the duration of assets. * **Legal Contingencies:** The company is currently pursuing a claim for higher land acquisition compensation (**₹30.02 Lacs** vs. **₹5.85 Lacs** received) against the government.